AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31573666
Drug: Topical skin
RxNorm normalized name: Betadine 7.5% Topical Skin Cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical skin formulation PT2 (4 strains of C. acnes SLST type C3 [55%], K8 [5%], A5 [30%] and F4 [10%])
Trial: 31573666
Drug: 5% benzoyl
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% benzoyl peroxide gel (active induction phase, 7 days)
Trial: 19748761
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus NMES for four weeks (daily stimulation to both thighs for up to 30 minutes, frequency 50Hz, 'on' cycle 11%-25%)
Trial: 17013637
Drug: Buprenorphine/naloxone (B/N)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone (B/N) 8/2 mg
Trial: 17013637
Drug: Buprenorphine/naloxone (B/N)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone (B/N) 16/4 mg
Trial: 17013637
Drug: Buprenorphine/naloxone (B/N)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone (B/N) 32/8 mg
Trial: 15232046
Drug: Interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal psychotherapy (12 weekly sessions)
Trial: 11371692
Drug: Zidovudine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (300 mg twice daily from 36‐38 weeks' gestation, 600 mg during labour, and 300 mg twice daily for 7 days post‐partum)
Trial: 3524797
Drug: Intermediate-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose methotrexate (IDM)
Trial: 31629306
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of amino acid mixture twice daily for 7 days
Trial: 29141739
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (2.7 × 10^5 PfSPZ)
Trial: 27307526
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage MTX (7.5 mg/week)
Trial: 27307526
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage MTX (20 mg/week)
Trial: 25491622
Drug: Continuous blood
RxNorm normalized name: Dexcom G6 Receiver Continuous Blood-Glucose M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous blood purification in combination with ulinastatin
Trial: 25491622
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment (oxygen inhalation, dynamic ECG monitoring, physical cooling methods)
Trial: 18650153
Drug: Ixabepilone 40
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone 40 mg/m2 plus capecitabine 1650-2000 mg/m2 (schedule A)
Trial: 18650153
Drug: Ixabepilone 8-10
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone 8-10 mg/m2 plus capecitabine 1650 mg/m2 (schedule B)
Trial: 18650153
Drug: Grade 3/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grade 3/4 treatment-related events in phase II
Trial: 16882128
Drug: Intravenous ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ibandronate 6 mg
Trial: 12514275
Drug: Beta-carotene (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (24 mg/d from an algal source)
Trial: 12514275
Drug: Carotenoid mix
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotenoid mix (24 mg/d consisting of beta-carotene, lutein, and lycopene at 8 mg/d each)
Trial: 8622025
Drug: Taxol (paclitaxel)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Taxol (paclitaxel) at a starting dose of 170 mg/m2 (135 mg/m2 for patients with prior pelvic radiation), given as a 24-hour continuous intravenous infusion every 3 weeks; dose adjustments allowed (escalations to 200 mg/m2 and deescalations to 110 mg/m2).
Trial: 1496731
Drug: 5.1-[NANP]19 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.1-[NANP]19 vaccine (50 or 400 micrograms doses)
Trial: 27334739
Drug: UMEC 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC 62.5 mcg added to ICS/LABA
Trial: 12959271
Drug: Remikiren 200
RxNorm normalized name: remikiren
DrugBank: Remikiren (DB00212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren 200 mg
Trial: 7769797
Drug: Remikiren 300
RxNorm normalized name: remikiren
DrugBank: Remikiren (DB00212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren 300 mg
Trial: 7769797
Drug: Remikiren 600
RxNorm normalized name: remikiren
DrugBank: Remikiren (DB00212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren 600 mg
Trial: 12959271
Drug: Remikiren 800
RxNorm normalized name: remikiren
DrugBank: Remikiren (DB00212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren 800 mg
Trial: 12959271
Drug: Remikiren (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren (various doses)
Trial: 2882766
Drug: Temazepam 0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam 0.5, 1.0 and 1.5 mg kg‐1 in an elixir formulation
Trial: 2882766
Drug: Trimeprazine tartrate
RxNorm normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimeprazine tartrate 3 mg kg‐1 in a syrup
Trial: 31464933
Drug: Acupuncture in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture in combination with prokinetic drugs
Trial: 31464933
Drug: Routine ICU
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine ICU treatment (Control)
Trial: 28669169
Drug: Age, tumor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, tumor size, tumor grade at diagnosis, hormone receptor status of estrogen and progesterone, Her-2
Trial: 26860019
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg intravenous 10 min before surgery)
Trial: 21732218
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (0.625 mg/day of conjugated equine estrogens)
Trial: 14705155
Drug: Anorexia nervosa
RxNorm normalized name: Syzygium nervosum flower bud extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anorexia nervosa treatment study
Trial: 11194932
Drug: Insulin suppression
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin suppression test modified with octreotide
Trial: 3098417
Drug: 6-hour iv
RxNorm normalized name: nitroglycerin 0.6 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-hour iv infusion of recombinant interferon-gamma (rIFN-gamma) at doses ranging from 0.016 to 0.65 mg/m2/day
Trial: 3098417
Drug: 24-hour iv
RxNorm normalized name: 24 Hour Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour iv infusion of recombinant interferon-gamma (rIFN-gamma) at doses ranging from 0.01 to 0.05 mg/m2/day
Trial: 30055991
Drug: Bilateral erector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral erector spinae plane (ESP) block with 3 mg/kg of 0.375% ropivacaine before anesthesia induction
Trial: 30055991
Drug: Paracetamol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1 gm every 6 hours) and tramadol (50 mg every 8 hours) intravenously
Trial: 30527177
Drug: Platinum-pemetrexed (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-pemetrexed (intravenous every 3 weeks for up to six cycles)
Trial: 27150079
Drug: Diazepam administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam administration (7-8 days)
Trial: 7848898
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous nitroglycerin infusion for the first 48 hours after acute MI
Trial: 7848898
Drug: Prolonged therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged therapy with nitrates spanning the healing phase of acute anterior Q-wave MI
Trial: 7848898
Drug: Long-term nitrate
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term nitrate therapy in patients with suspected MI
Trial: 3396474
Drug: Single-dose cefotaxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose cefotaxime (1g)
Trial: 29794563
Drug: Continuous sciatic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous sciatic nerve blockade with 5 ml/h ropivacaine 0.2% (CO)
Trial: 29794563
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection sciatic nerve blockade with 5 ml/h saline infusion (SIN)
Trial: 29794563
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection sciatic nerve blockade (SIN)
Trial: 26568249
Drug: Grape Seed
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape Seed Extract (GSE) 300 mg/d (150 mg twice daily) for 6 weeks
Trial: 26568249
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg GSE) for 6 weeks
Trial: 25870665
Drug: Intravitreal administration
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal administration of triamcinolone acetonide
Trial: 25870665
Drug: Intravitreal administration
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal administration of triamcinolone acetonide in combination with bevacizumab
Trial: 22445441
Drug: Doubling of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling of statin dose
Trial: 20491720
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy for psychosis (CBTp)
Trial: 18949295
Drug: Ca(OH)2 +
RxNorm normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca(OH)2 + 2% chlorhexidine gluconate (CHX) gel
Trial: 12182236
Drug: Domperidone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (10 mg orally)
Trial: 8776184
Drug: Autotransfusion without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Autotransfusion without heparin-bonded circuit (Group 2)
Trial: 8776184
Drug: Autotransfusion with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autotransfusion with heparin-bonded circuit (Group 3)
Trial: 1632172
Drug: Vf of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vf of 50 ml.kg‐1.min‐1 (Group 1)
Trial: 1632172
Drug: Vf of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vf of 75 ml.kg‐1.min‐1 (Group 2)
Trial: 1632172
Drug: Vf of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vf of 100 ml.kg‐1.min‐1 (Group 3)
Trial: 1632172
Drug: Vf of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vf of 100 ml.kg‐1.min‐1 for 15 min, 75 ml.kg‐1.min‐1 for the next 15 min and 50 ml.kg‐1.min‐1 thereafter (Group 4)
Trial: 1632172
Drug: Vf of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vf of 25 ml.kg‐1.min‐1 for 10 min and switched off for the remainder of the procedure (Group 5)
Trial: 29684771
Drug: CoQ10 supplementation
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 supplementation at a daily dose of 30 mg for 100 days
Trial: 29684771
Drug: CoQ10 supplementation
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 supplementation at a daily dose of 60 mg for 100 days
Trial: 24290594
Drug: Yeast hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast hydrolysate 1 g/d
Trial: 24290594
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 g/d
Trial: 20850091
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of abciximab through the guiding catheter
Trial: 20850091
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of abciximab
Trial: 12577328
Drug: Combined HACE
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined HACE and Chinese herbal medicine (Gan'ai No. I and No. II)
Trial: 3034690
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of LTB4
Trial: 3034690
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 12-HETE
Trial: 3034690
Drug: Control lesions
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control lesions (not specified treatment)
Trial: 2543582
Drug: Natural or
RxNorm normalized name: Dex4 Natural Orange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural or synthetic retinoids (RA, acitretin, isotretinoin, Ro137410, retinol) applied daily for 4 days
Trial: 2543582
Drug: Topical dithranol
RxNorm normalized name: Zithranol
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dithranol treatment, UVB irradiation, or scotch tape stripping
Trial: 2543582
Drug: Topical diflucortolone
RxNorm normalized name: diflucortolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diflucortolone
Trial: 17880315
Drug: Peripheral intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral intravenous catheter
Trial: 21348213
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of ephedrine intravenously (EPHE‐5)
Trial: 21348213
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of ephedrine intravenously (EPHE‐10)
Trial: 21348213
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of HES 130/0.4 in rapid infusion over 15 minutes
Trial: 19130635
Drug: Auricular acupuncture
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupuncture treatment group
Trial: 11515884
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g bolus before skin incision, followed by continuous infusion of 400 mg/hr during surgery)
Trial: 8498877
Drug: New psychopharmacologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New psychopharmacologic treatments
Trial: 23590271
Drug: Dead space
RxNorm normalized name: UltiCare 3mL 22G 1-1/2 inch Low Dead Space Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dead space (DS) loading of 0.6 L during exercise
Trial: 23590271
Drug: Dead space
RxNorm normalized name: UltiCare 3mL 22G 1-1/2 inch Low Dead Space Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dead space (DS) loading of 0.6 L at 60 W
Trial: 19221371
Drug: Drug facts
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug facts box in symptom drug box trial
Trial: 19221371
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (actual drug ads) in symptom drug box trial
Trial: 19221371
Drug: Drug facts
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug facts box in prevention drug box trial
Trial: 19221371
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (actual drug ads) in prevention drug box trial
Trial: 22142537
Drug: SunshowerMedical home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SunshowerMedical home UV device, used daily for 6 minutes over 6 weeks
Trial: 22142537
Drug: Hospital UVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital UVB treatment (Waldmann 85/UV21 lamps), twice a week for 6 weeks
Trial: 21456039
Drug: Fluoxetine 40
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 40 mg/day plus modafinil 400 mg/day (200 mg bid)
Trial: 19496103
Drug: Fluoxetine 40
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 40 mg/day plus placebo
Trial: 16522393
Drug: Antibiotics (metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (metronidazole 250 mg and erythromycin 250 mg tid orally for 7 days prenatally, metronidazole 250 mg and ampicillin 500 mg q 4 hours during labor)
Trial: 16522393
Drug: Antibiotics and
RxNorm normalized name: Antibiotics and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics and Placebo
Trial: 8982890
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block with 1.5 ml/kg of 0.2% bupivacaine (Group I)
Trial: 8982890
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration of the surgical site with up to 1.2 ml/kg of 0.25% bupivacaine (Group 2)
Trial: 6099055
Drug: Etomidate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.3 mg/kg body wt.)
Trial: 6099055
Drug: Thiopentone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (4 mg/kg body wt.)
Trial: 19104775
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 60 mg
Trial: 2044903
Drug: Oral omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral omeprazole (80 mg)
Trial: 6266642
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with MER (methanol-extracted residue of bacillus Calmette-Guerin)
Trial: 6266642
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy without MER
Trial: 22940119
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone once daily from the day after insemination until 12 weeks of pregnancy or for 14 days in non-pregnant women
Trial: 20590478
Drug: SJW 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJW 300 mg
Trial: 20590478
Drug: SJW 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJW 600 mg
Trial: 17566826
Drug: Rectal contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal contrast CT
Trial: 12394765
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose intravesical BCG (120 mg)
Trial: 12394765
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose intravesical BCG (40 mg)
Trial: 12394765
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of intravesical BCG
Trial: 9783492
Drug: Perindopril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (ACE inhibitor) alone or in combination with indapamide (diuretic)
Trial: 8197045
Drug: Erythromycin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 1.0 g/day for 10 days
Trial: 2853457
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (16 mg daily)
Trial: 25919011
Drug: Pain Exposure
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Exposure Physical Therapy
Trial: 12507208
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy plus radiation therapy
Trial: 10457792
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg once daily for 2 weeks, then increased to 10 mg once daily if diastolic blood pressure did not fall below 90 mmHg
Trial: 30284065
Drug: Egg ovalbumin-derived
RxNorm normalized name: ovalbumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg ovalbumin-derived protein hydrolysate (3 g/day)
Trial: 30284065
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 g/day)
Trial: 28646591
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cryotherapy and salicylic acid